Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Vaxneuvance by Quarter
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — U.S. reported growth YoY (%) (%)
Merck Vaxneuvance: -50.0% in Q2 2026, down 88.0 pts from a year earlier.
Latest, Q2 2026
-50.0%
Period ended Jun 30, 2026
Change on a year earlier
-88.0 pts
38.0% in Q2 2025
History
10 quarters
Since Q4 2023
Sources
10
Documents cited below
Where the Q2 2026 figure comes from
“|| Vaxneuvance | 148 | 229 | -35 | 69 | 136 | -50 | 80 | 93 | -14”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vaxneuvance (15-valent pneumococcal conjugate vaccine) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -50.0% | -88.0 pts | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| Q4 2025 | Dec 31, 2025 | -22.0% | +31.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | -1.0% | +24.0 pts | Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 38.0% | +71.0 pts | Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗ |
| Q1 2025 | Mar 31, 2025 | -14.0% | -86.0 pts | Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗ |
| Q4 2024 | Dec 31, 2024 | -53.0% | -58.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| Q3 2024 | Sep 30, 2024 | -25.0% | – | Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗ |
| Q2 2024 | Jun 30, 2024 | -33.0% | – | Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗ |
| Q1 2024 | Mar 31, 2024 | 72.0% | – | Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗ |
| Q4 2023 | Dec 31, 2023 | 5.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
Cite this data
StockData. (2026). Merck Vaxneuvance (%), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-vaxneuvance-us-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.